

For Immediate Release

MedX Health Corp. To Commence Trading On TSX Venture

Mississauga, Ontario - February 11, 2008 – **MedX Health Corp.** (TSXV: MDX) ("**MedX**" or the "**Company**"), a leading North American developer and manufacturer of phototherapy medical devices, is pleased to announce that, effective with the market opening on Tuesday, February 12, 2008, the common shares of the Company will commence trading on the TSX Venture Exchange ("**TSXV**") under the stock symbol MDX. MedX's listing is considered a new listing with a Tier 2 classification as a medical device manufacturing company.

The net proceeds of the Company's recent public offering will be used for expansion of distribution network, marketing program, product development for new dental, rehabilitation and wound care products, research and development for wound care study and for working capital purposes. In particular, MedX plans to accelerate the development of a new product aimed at the rapidly-growing wound care market: its *"PhotoBandage"*, a bandage technology that allows a wound to be bathed in light, designed to enhance the healing process. The Company intends to license this new technology to one or more major wound care companies for further development, marketing and sales.

"We are all very excited to be in a position to be able to proceed with our business plan," said Phil Passy, MedX's President and Chief Executive Officer. "Being listed on the TSXV gives us liquidity which will help us access the capital market. We believe that the healing power of light is only now starting to be broadly appreciated. It is our mission to be a leading provider of phototherapy products that bring the phototherapy products to the large population of people."

For further information, please contact:

Phil Passy President and Chief Executive Officer Phone: (905) 826-0766 Email: <u>investor@medxhealth.com</u>

The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this press release.

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information may include statements regarding the Company's future plans, objectives, performance, growth, profits, operating expenses or its underlying assumptions. Generally, forward-looking information can be identified by the use of forward-looking terminology such as "plans", "expects", or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "does not anticipate", or "believes" or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might", or "will be taken", "occur", or "be achieved". Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of MedX to be materially different from those expressed or implied by such forward-looking information, including uncertainty of successful development of new products, uncertainty of successful manufacturing or marketing of products, uncertainty of commercial acceptance of products, uncertainty concerning governmental regulation, dependency on key employees and relationships, rapid technological changes, foreign currency fluctuations. MedX does not undertake to update any forward-looking information, except in accordance with applicable securities laws.